Jacob Bell
New Member
Author(s) Plasse T, Conant M, Gorter R, Shepard KV
Journal, Volume, Issue International Conference on AIDS 1992;8(3):122 (abstract no. PuB 7442)
Major outcome(s) increase in appetite, trend toward weight gain
Indication HIV/AIDS; Appetite loss/weight loss; Depression
Medication Delta-9-THC
Route(s) Oral
Dose(s) 2.5 mg twice daily
Duration (days) 28
Participants 40 patients with AIDS
Design Controlled study
Type of publication
Address of author(s) UNIMED Inc., Somerville, NJ., USA
Abstract
OBJECTIVE: To test the effect of dronabinol (delta-9- tetrahydrocannabinol) on appetite and weight in symptomatic HIV patients (pts). METHODS: Forty pts with symptomatic HIV infection who were actively losing weight were entered into this dose ranging study of dronabinol (Marinol, Roxane Laboratories, Columbus OH). After a one week baseline period, pts were treated for 4 weeks; to be evaluable for efficacy, patients had to receive at least 3 weeks' medication. Pts were weighed and completed a questionnaire on physical and psychological symptoms weekly; they completed 100mm visual analog scales for hunger before each meal. Of 40 pts entered, 10 withdrew due to suspected adverse effects of study medication and 7 due to other causes. RESULTS: TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS: In this open pilot study, dronabinol 2.5 mg bid was well tolerated and caused a significant increase in appetite, improvement of symptoms and a strong trend toward weight gain.
Source: Dronabinol Stimulates Appetite and Causes Weight Gain in HIV Patients
Journal, Volume, Issue International Conference on AIDS 1992;8(3):122 (abstract no. PuB 7442)
Major outcome(s) increase in appetite, trend toward weight gain
Indication HIV/AIDS; Appetite loss/weight loss; Depression
Medication Delta-9-THC
Route(s) Oral
Dose(s) 2.5 mg twice daily
Duration (days) 28
Participants 40 patients with AIDS
Design Controlled study
Type of publication
Address of author(s) UNIMED Inc., Somerville, NJ., USA
Abstract
OBJECTIVE: To test the effect of dronabinol (delta-9- tetrahydrocannabinol) on appetite and weight in symptomatic HIV patients (pts). METHODS: Forty pts with symptomatic HIV infection who were actively losing weight were entered into this dose ranging study of dronabinol (Marinol, Roxane Laboratories, Columbus OH). After a one week baseline period, pts were treated for 4 weeks; to be evaluable for efficacy, patients had to receive at least 3 weeks' medication. Pts were weighed and completed a questionnaire on physical and psychological symptoms weekly; they completed 100mm visual analog scales for hunger before each meal. Of 40 pts entered, 10 withdrew due to suspected adverse effects of study medication and 7 due to other causes. RESULTS: TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS: In this open pilot study, dronabinol 2.5 mg bid was well tolerated and caused a significant increase in appetite, improvement of symptoms and a strong trend toward weight gain.
Source: Dronabinol Stimulates Appetite and Causes Weight Gain in HIV Patients
